Tofacitinib Prodrug-1
Tofacitinib Prodrug-1 is an orally active prodrug designed to reduce the systemic side effects of tofacitinib. It has demonstrated efficacy in attenuating oxazolone-induced colitis in murine models, indicating its potential as a therapeutic candidate for ulcerative colitis. Its research applications include investigating prodrug strategies and JAK/STAT pathway inhibition in inflammatory bowel disease models.
Product Specifications
Field of Research
Cardiovascular Research, Cell Biology, Epigenetics & Chromatin, Pharmacology & Drug Discovery, Signal Transduction, Stem Cell & Developmental Biology
Smiles
C[C@@H]1CCN (C (CC#N) =O) C[C@H]1CNC2=C3C=CN (C (N (CCCNC (OCC4=C (Cl) C=C (N=NC5=CC (C (O) =O) =C (O) C=C5) C=C4) =O) C) =O) C3=NC=N2
Molecular Formula
C36H39ClN10O7
Molecular Weight
759.21
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MART-1 / Melan-A (M2-7C10), CF647 conjugate, 0.1mg/mL
Cytokeratin, HMW (AE-3), CF594 conjugate, 0.1mg/mL
MUC1 / EMA / CD227 (Epithelial Marker) (rMUC1/960), CF640R conjugate, 0.1mg/mL
TRAcP (Tartarate Resistant Acid Phosphatase) (ACP5/1070), CF640R conjugate, 0.1mg/mL
